Abstract 6501: Development and characterization of covalent inhibitors of the RAS-PIK3CA interaction
Joseph E. Klebba(Vividion Therapeutics (United States)), Matt Patricelli(Vividion Therapeutics (United States)), Hui Miao(National University of Singapore), Kelsey N. Lamb(Vividion Therapeutics (United States)), Chanyu Yue(Vividion Therapeutics (United States)), Melissa Hoffman(University of Cincinnati), Todd M. Kinsella(Vividion Therapeutics (United States)), Aaron N. Snead(Vividion Therapeutics (United States)), Holly Parker(Vividion Therapeutics (United States)), Steffen M. Bernard(Vividion Therapeutics (United States)), Stephanie Grabow(Dana-Farber Cancer Institute), Marie Pariollaud(Scripps Research Institute), Taylor E. Wyrick(Vividion Therapeutics (United States)), Junko Tamiya(Vividion Therapeutics (United States)), Antonio Esparza-Oros(Vividion Therapeutics (United States)), Jinwei Wang, David Weinstein(Vividion Therapeutics (United States)), Martha K. Pastuszka(Vividion Therapeutics (United States)), J. Sigler(Vividion Therapeutics (United States)), BENJAMIN HORNING(Vividion Therapeutics (United States)), Yongsheng Liu(Vividion Therapeutics (United States)), Richard Z. Lin(The University of Sydney)
Cited by 1
Related Papers
Trends in Chronic Kidney Disease in China
|New England Journal of Medicine|2016|796
An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action
|Nature Medicine|2014|463
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
|European Heart Journal|2018|323
Circadian clock component REV-ERBα controls homeostatic regulation of pulmonary inflammation
|Journal of Clinical Investigation|2018|208